Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women with Suspected Ovarian Cancer

Emil Lou; Rachel I. Vogel; Deanna Teoh; Spencer Hoostal; Aaron Grad; Matthew Gerber; Minnu Monu; Tomasz Lukaszewski; Jaai Deshpande; Michael A. Linden; Melissa A. Geller

doi:10.1093/labmed/lmx084

Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women with Suspected Ovarian Cancer

Emil Lou, Rachel I. Vogel, Deanna Teoh, Spencer Hoostal, Aaron Grad, Matthew Gerber, Minnu Monu, Tomasz Lukaszewski, Jaai Deshpande, Michael A. Linden, Melissa A. Geller

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Background The clinical assessment of circulating tumor cells (CTCs) as a blood-based biomarker is FDA-approved for use in breast, colorectal, and prostate cancers. The objective of this prospective clinical study was to determine whether pretreatment CTCs are a useful diagnostic biomarker in women with complex pelvic masses. Methods Whole blood was collected from 49 women with newly diagnosed pelvic masses. The presence of CTCs was compared between women with and without ovarian cancer histopathologic diagnosis after surgery using a Chi-squared test. Results CTCs were absent in those with benign disease (0/14), present in 17% (5/29) of patients with a histologic diagnosis of ovarian carcinoma, and present in 80% (4/5) of patients with ovarian metastases from other cancers (P = 0.001). All 5 women with ovarian cancer who had CTCs present presented stage III or IV of the disease (P = 0.13). Conclusions CTCs were more prevalent in patients with metastases to the ovary than in primary ovarian carcinomas.

Original language	English (US)
Pages (from-to)	134-139
Number of pages	6
Journal	Lab Medicine
Volume	49
Issue number	2
DOIs	https://doi.org/10.1093/labmed/lmx084
State	Published - Mar 21 2018

Bibliographical note

Funding Information:
This research was supported by a NIH Clinical and Translational Science KL2 Scholar Award 8UL1TR000114 (to E.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding support came from the Litman Family Fund for Cancer Research; the University of Minnesota Deborah E. Powell Center for Women’s Health Interdisciplinary Seed Grant support (Grant #PCWH-2013-002) (E.L.); Minnesota Masonic Charities; the Masonic Cancer Center (Grant # P30 CA77598) and Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota.

Publisher Copyright:
© American Society for Clinical Pathology 2018. All rights reserved.

Keywords

Krukenberg tumors
biomarkers
circulating tumor cells
ovarian cancer
ovarian mass
pelvic mass

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1093/labmed/lmx084

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251585

OpenUrl availability

Full text

Cite this

@article{6bcee33c757b45528ea9694366c239fa,

title = "Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women with Suspected Ovarian Cancer",

abstract = "Background The clinical assessment of circulating tumor cells (CTCs) as a blood-based biomarker is FDA-approved for use in breast, colorectal, and prostate cancers. The objective of this prospective clinical study was to determine whether pretreatment CTCs are a useful diagnostic biomarker in women with complex pelvic masses. Methods Whole blood was collected from 49 women with newly diagnosed pelvic masses. The presence of CTCs was compared between women with and without ovarian cancer histopathologic diagnosis after surgery using a Chi-squared test. Results CTCs were absent in those with benign disease (0/14), present in 17% (5/29) of patients with a histologic diagnosis of ovarian carcinoma, and present in 80% (4/5) of patients with ovarian metastases from other cancers (P = 0.001). All 5 women with ovarian cancer who had CTCs present presented stage III or IV of the disease (P = 0.13). Conclusions CTCs were more prevalent in patients with metastases to the ovary than in primary ovarian carcinomas.",

keywords = "Krukenberg tumors, biomarkers, circulating tumor cells, ovarian cancer, ovarian mass, pelvic mass",

author = "Emil Lou and Vogel, {Rachel I.} and Deanna Teoh and Spencer Hoostal and Aaron Grad and Matthew Gerber and Minnu Monu and Tomasz Lukaszewski and Jaai Deshpande and Linden, {Michael A.} and Geller, {Melissa A.}",

note = "Funding Information: This research was supported by a NIH Clinical and Translational Science KL2 Scholar Award 8UL1TR000114 (to E.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding support came from the Litman Family Fund for Cancer Research; the University of Minnesota Deborah E. Powell Center for Women{\textquoteright}s Health Interdisciplinary Seed Grant support (Grant #PCWH-2013-002) (E.L.); Minnesota Masonic Charities; the Masonic Cancer Center (Grant # P30 CA77598) and Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota. Publisher Copyright: {\textcopyright} American Society for Clinical Pathology 2018. All rights reserved.",

year = "2018",

month = mar,

day = "21",

doi = "10.1093/labmed/lmx084",

language = "English (US)",

volume = "49",

pages = "134--139",

journal = "Lab Medicine",

issn = "0007-5027",

publisher = "American Society of Clinical Pathologists",

number = "2",

}

TY - JOUR

T1 - Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women with Suspected Ovarian Cancer

AU - Lou, Emil

AU - Vogel, Rachel I.

AU - Teoh, Deanna

AU - Hoostal, Spencer

AU - Grad, Aaron

AU - Gerber, Matthew

AU - Monu, Minnu

AU - Lukaszewski, Tomasz

AU - Deshpande, Jaai

AU - Linden, Michael A.

AU - Geller, Melissa A.

N1 - Funding Information: This research was supported by a NIH Clinical and Translational Science KL2 Scholar Award 8UL1TR000114 (to E.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding support came from the Litman Family Fund for Cancer Research; the University of Minnesota Deborah E. Powell Center for Women’s Health Interdisciplinary Seed Grant support (Grant #PCWH-2013-002) (E.L.); Minnesota Masonic Charities; the Masonic Cancer Center (Grant # P30 CA77598) and Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota. Publisher Copyright: © American Society for Clinical Pathology 2018. All rights reserved.

PY - 2018/3/21

Y1 - 2018/3/21

N2 - Background The clinical assessment of circulating tumor cells (CTCs) as a blood-based biomarker is FDA-approved for use in breast, colorectal, and prostate cancers. The objective of this prospective clinical study was to determine whether pretreatment CTCs are a useful diagnostic biomarker in women with complex pelvic masses. Methods Whole blood was collected from 49 women with newly diagnosed pelvic masses. The presence of CTCs was compared between women with and without ovarian cancer histopathologic diagnosis after surgery using a Chi-squared test. Results CTCs were absent in those with benign disease (0/14), present in 17% (5/29) of patients with a histologic diagnosis of ovarian carcinoma, and present in 80% (4/5) of patients with ovarian metastases from other cancers (P = 0.001). All 5 women with ovarian cancer who had CTCs present presented stage III or IV of the disease (P = 0.13). Conclusions CTCs were more prevalent in patients with metastases to the ovary than in primary ovarian carcinomas.

AB - Background The clinical assessment of circulating tumor cells (CTCs) as a blood-based biomarker is FDA-approved for use in breast, colorectal, and prostate cancers. The objective of this prospective clinical study was to determine whether pretreatment CTCs are a useful diagnostic biomarker in women with complex pelvic masses. Methods Whole blood was collected from 49 women with newly diagnosed pelvic masses. The presence of CTCs was compared between women with and without ovarian cancer histopathologic diagnosis after surgery using a Chi-squared test. Results CTCs were absent in those with benign disease (0/14), present in 17% (5/29) of patients with a histologic diagnosis of ovarian carcinoma, and present in 80% (4/5) of patients with ovarian metastases from other cancers (P = 0.001). All 5 women with ovarian cancer who had CTCs present presented stage III or IV of the disease (P = 0.13). Conclusions CTCs were more prevalent in patients with metastases to the ovary than in primary ovarian carcinomas.

KW - Krukenberg tumors

KW - biomarkers

KW - circulating tumor cells

KW - ovarian cancer

KW - ovarian mass

KW - pelvic mass

UR - http://www.scopus.com/inward/record.url?scp=85044667439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044667439&partnerID=8YFLogxK

U2 - 10.1093/labmed/lmx084

DO - 10.1093/labmed/lmx084

M3 - Article

C2 - 29361118

AN - SCOPUS:85044667439

SN - 0007-5027

VL - 49

SP - 134

EP - 139

JO - Lab Medicine

JF - Lab Medicine

IS - 2

ER -

Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women with Suspected Ovarian Cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this